A recent phase 3 study shows that combining the targeted therapy osimertinib with chemotherapy may revolutionize treatment for patients with advanced EGFR-mutated lung cancer. Investigators report unprecedented survival rates, sparking optimism for significantly improved outcomes in this patient group.